[pneumonic]

“I advise strongly against trying to pursue ketamine, commercially or clinically, because of safety concerns and the risk of losing our opportunity to study it rigorously,” said Kolevzon [the clinical director]

Research to gain quality evidence is good, but sometimes other considerations outweigh that. Visible improvement in the sufferers of a rare disease may be such a case.